NurExone's ExoPTEN Shows Promising Results in Spinal Cord Injury and Glaucoma Preclinical Studies
Key Insights
NurExone's ExoPTEN therapy demonstrated 100% recovery of walking ability in animals with spinal cord injuries when treated with higher doses, compared to only 1 out of 6 untreated animals achieving this milestone.
Preclinical studies for glaucoma (search) treatment showed dose-dependent therapeutic effects, with high-dose ExoPTEN achieving response amplitudes comparable to uninjured eyes in optic nerve injury models.
The company plans to initiate Phase 1/2a clinical trials for acute spinal cord injuries in 2026, targeting adult patients with traumatic injuries between spinal levels C5 and T10.
NurExone Biosciences (search) has reported significant preclinical results for its ExoPTEN therapy, demonstrating remarkable efficacy in treating both spinal cord injuries and optic nerve damage (search). The exosome-based treatment showed complete functional recovery in animal models, positioning the company for human clinical trials in 2026.
Breakthrough Results in Spinal Cord Injury Treatment
In preclinical studies conducted on small animals, ExoPTEN demonstrated unprecedented success rates in treating spinal cord injuries. Animals received varying doses of ExoPTEN on the day of spinal compression surgery, with results showing that 100% of animals treated with the higher dose regained walking ability in both front and hind legs. In stark contrast, only 1 out of 6 untreated animals achieved this milestone.
The company plans to advance to Phase 1/2a clinical trials for acute spinal cord injuries in 2026. The study will involve adult patients with traumatic spinal cord injuries between spinal levels C5 and T10, with treatment administered within 3 to 7 days post-injury.
Promising Glaucoma Treatment Data
ExoPTEN also showed significant promise in treating optic nerve damage (search) associated with conditions such as glaucoma (search). In a preclinical study conducted at the Goldschleger Eye Institute (search) at Sheba Medical Center, researchers demonstrated that ExoPTEN's biological activity increases with higher dosing levels, confirming reproducibility standards.
Functional measurements using scotopic threshold response electroretinography (STR-ERG) revealed that both ExoPTEN doses improved visual signal strength in animals with optic nerve injury. The high-dose group achieved response amplitudes comparable to those of uninjured eyes, demonstrating substantial functional recovery and providing clear evidence of a dose-dependent therapeutic effect.
Dr. Ifat Sher, lead investigator at the Goldschleger Eye Institute (search), commented on the results: "The results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures, and preserved retinal ganglion cells (search). These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma (search) and optic nerve trauma."
Regulatory Recognition and Market Potential
ExoPTEN has received Orphan Drug Designation from both the FDA in the United States (2023) and Orphan Medicinal Product Designation from the European Medicines Agency (search) (EMA). These designations provide significant incentives including:
- Ten years of market exclusivity upon approval (EMA)
- Seven years of market exclusivity after approval (FDA)
- Tax credits for qualified clinical trials
- Exemption from user fees
- Access to grants and reduced-cost scientific advice
The glaucoma (search) treatment market represents a significant opportunity, with current estimates of approximately $5.5 billion and a projected annual growth rate of over 8%.
Technology Foundation and Intellectual Property
ExoPTEN is based on intranasal administration of exosomes (search) derived from mesenchymal stem cells (search) loaded with siRNA. The technology originated from university research conducted between January 2017 and May 2020, with testing targeting complete spinal cord transection in rats using the strictest animal testing model.
NurExone has secured an exclusive worldwide license from the Technion (search) and Tel Aviv University to develop and commercialize the technology. The company has also developed its own intellectual property portfolio, now encompassing five families of patents. Recently, the US Patent and Trademark Office issued a Notice of Allowance for a patent covering the company's proprietary exosome production process.
Manufacturing and Commercial Development
The company's US subsidiary has demonstrated that their exosomes (search) significantly outperform recognized commercial industry standards in key healing applications. Jacob Licht, CEO of the US subsidiary, stated: "This data confirms that the naïve exosomes that will be manufactured by our U.S. subsidiary will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care, and orthopedic tissue repair."
The exosomes (search) are produced from NurExone's own cell bank under strict environmental controls and are reproducible at the same high-performance level, supporting the scalability of the manufacturing process.